Close Menu

financial results

The firm is lowering its guidance due to anticipated revenue loss related to remediation efforts associated with its Alaris pump system.

Contributing to the Japanese diagnostic firm's higher revenues were increased instrument and reagent sales both domestically and internationally.

Qiagen's Q4 revenues of $413.5 million represented 4 percent growth at constant exchange rates and bested Wall Street's expectation of $405.6 million.

The firm said that in fiscal Q2, its China businesses continued to achieve greater than 20 percent growth, but its European business growth was soft year over year.

Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month. 

The company announced Monday that it has inked a contract to become the primary supplier of products for immunoassay testing to Quest Diagnostics.

China remains a key strategic market for Roche, and it said that it has multiple assays for 2019-nCoV coronavirus for research-use only. 

Revenues for the quarter were $1.93 billion, with the company attributing the growth to expanded access to insurer networks and good operational execution.

While overall revenues and net income were up, analytical instruments revenues decreased 3 percent in Q4, and 2 percent organically.

Roche's overall revenues increased 9 percent, with an 11 percent increase in pharmaceuticals along with the rise in diagnostics revenues.

Pages